Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. Geron Corporation (NASDAQ:GERN) stock performance was 4.01% in last session and finished the day at $3.11. Traded volume was 5.47million shares in the last session and the average volume of the stock remained 5.27million shares. The beta of the stock remained 1.64. Geron Corporation (NASDAQ:GERN) insider ownership is 0.40%.

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) is undervalued by Merck & Co. (MRK:US)’s $3.9 billion takeover offer, a shareholder said in a lawsuit seeking to block the deal. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) rose 0.13 percent to $23.99 Tuesday on volume of 5.72million shares. The intra-day range of the stock was $23.79 to $24.00. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has a market capitalization of $3.62billion.

Some better-ranked stocks in the same industry include Biomerica Inc. ( BMRA ), POZEN Inc. ( POZN ) and Ariad Pharmaceuticals Inc. (NASDAQ:ARIA). While Biomerica and POZEN hold a Zacks Rank #1 (Strong Buy), Ariad Pharmaceuticals Inc (NASDAQ:ARIA)carries a Zacks Rank #2 (Buy). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on June 17, 2014 reported a decrease of -1.16% to the closing price of $6.38. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.19billion. The overall volume in the last trading session was 6.30million shares. In its share capital, ARIA has 186.80million outstanding shares.

Aveo Pharmaceuticals, Inc. (NASDAQ:AVEO) is the classic asymmetric investment.  It has huge upside potential with very little downside risk.  The company has $1.71 in cash per share and sells for just $1.20 per share. That means the company has more cash on its balance sheet than its entire market capitalization. In addition, it’s owned by the same billionaire investor, Seth Klarman, who owned Idenix — the stock that was acquired for a 230% premium this week. On Tuesday, shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) advanced 11.43% to close the day at $1.56. Company return on investment (ROI) is -116.60% and its monthly performance is recorded as -8.24%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly revenue growth is -8.24%.

Gilead Sciences, Inc. (NASDAQ:GILD), maker of Sovaldi has developed a new hepatitis C treatment that does not require the use of interferon. The pill is nearing approval, but the price is yet to be disclosed. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -1.21% in last session and finished the day at $79.79. Traded volume was 11.14million shares in the last session and the average volume of the stock remained 16.25million shares. The beta of the stock remained 0.70. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.